JP2016535795A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535795A5 JP2016535795A5 JP2016553270A JP2016553270A JP2016535795A5 JP 2016535795 A5 JP2016535795 A5 JP 2016535795A5 JP 2016553270 A JP2016553270 A JP 2016553270A JP 2016553270 A JP2016553270 A JP 2016553270A JP 2016535795 A5 JP2016535795 A5 JP 2016535795A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorophenyl
- pharmaceutical composition
- oxopiperidin
- methylbutan
- isopropylsulfonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 238000000034 method Methods 0.000 claims 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 5
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 5
- -1 3-methyl-2-oxopiperidin-3-yl Chemical group 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 3
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 229960002465 dabrafenib Drugs 0.000 claims 2
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 2
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- DRLCSJFKKILATL-YWCVFVGNSA-N 2-[(3r,5r,6s)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2s)-3-methyl-1-propan-2-ylsulfonylbutan-2-yl]-2-oxopiperidin-3-yl]acetic acid Chemical compound C1([C@@H]2[C@H](N(C([C@@](C)(CC(O)=O)C2)=O)[C@H](CS(=O)(=O)C(C)C)C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC(Cl)=C1 DRLCSJFKKILATL-YWCVFVGNSA-N 0.000 claims 1
- 102200055464 rs113488022 Human genes 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361902717P | 2013-11-11 | 2013-11-11 | |
| US61/902,717 | 2013-11-11 | ||
| PCT/US2014/065034 WO2015070224A2 (en) | 2013-11-11 | 2014-11-11 | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019078325A Division JP2019142916A (ja) | 2013-11-11 | 2019-04-17 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016535795A JP2016535795A (ja) | 2016-11-17 |
| JP2016535795A5 true JP2016535795A5 (enExample) | 2017-12-21 |
Family
ID=52001089
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016553270A Ceased JP2016535795A (ja) | 2013-11-11 | 2014-11-11 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2019078325A Pending JP2019142916A (ja) | 2013-11-11 | 2019-04-17 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2020172367A Expired - Fee Related JP6972274B2 (ja) | 2013-11-11 | 2020-10-13 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2021178554A Pending JP2022009805A (ja) | 2013-11-11 | 2021-11-01 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2023003579A Pending JP2023033414A (ja) | 2013-11-11 | 2023-01-13 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019078325A Pending JP2019142916A (ja) | 2013-11-11 | 2019-04-17 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2020172367A Expired - Fee Related JP6972274B2 (ja) | 2013-11-11 | 2020-10-13 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2021178554A Pending JP2022009805A (ja) | 2013-11-11 | 2021-11-01 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
| JP2023003579A Pending JP2023033414A (ja) | 2013-11-11 | 2023-01-13 | Ｍｄｍ２阻害剤及び１つ以上の追加の医薬活性剤を含む癌治療のための併用療法 |
Country Status (33)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160061439A (ko) | 2007-03-28 | 2016-05-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| WO2012021875A1 (en) | 2010-08-13 | 2012-02-16 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with triazole linkers |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| JP6342808B2 (ja) | 2011-10-18 | 2018-06-13 | エイルロン セラピューティクス，インコーポレイテッド | ペプチドミメティック大環状化合物 |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| SMT202200241T1 (it) * | 2013-11-11 | 2022-09-14 | Amgen Inc | Politerapia che include un inibitore di mdm2 e uno o più agenti farmaceuticamente attivi aggiuntivi per il trattamento di cancri |
| EP3197477A4 (en) | 2014-09-24 | 2018-07-04 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
| SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| WO2016133194A1 (ja) | 2015-02-20 | 2016-08-25 | 第一三共株式会社 | がんの併用治療法 |
| AU2016235424A1 (en) | 2015-03-20 | 2017-10-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN108348611A (zh) * | 2015-08-28 | 2018-07-31 | 诺华股份有限公司 | 使用pi3k抑制剂和mdm2抑制剂的联合疗法 |
| EP3340989B1 (en) * | 2015-08-28 | 2023-08-16 | Novartis AG | Mdm2 inhibitors and combinations thereof |
| WO2017200826A1 (en) * | 2016-05-16 | 2017-11-23 | Albert Einstein College Of Medicine, Inc. | Assays and compounds for treatment of cancer |
| ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
| CN109843329A (zh) * | 2016-10-17 | 2019-06-04 | 第一三共株式会社 | 使用mdm2抑制剂和dna甲基转移酶抑制剂的组合治疗方法 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| IL308399B2 (en) | 2018-04-30 | 2025-08-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| MX2020012503A (es) * | 2018-05-25 | 2021-08-11 | Kartos Therapeutics Inc | Métodos de tratamiento de neoplasias mieloproliferativas. |
| WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN110963958B (zh) * | 2018-09-30 | 2025-10-10 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| AR116904A1 (es) * | 2018-12-11 | 2021-06-23 | Kartos Therapeutics Inc | Métodos y composiciones para el tratamiento de un trastorno oftálmico |
| CN111434353A (zh) * | 2019-02-02 | 2020-07-21 | 中国科学院上海营养与健康研究所 | Ras抑制剂筛选及疗效标志物 |
| AU2020323033A1 (en) | 2019-07-26 | 2021-04-22 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| US20230218575A1 (en) * | 2020-06-15 | 2023-07-13 | Ascentage Pharma (Suzhou) Co., Ltd. | Microsuspension of an mdm2 inhibitor and therapeautic applications thereof |
| WO2022036067A1 (en) * | 2020-08-12 | 2022-02-17 | Servier Pharmaceuticals, Llc | Combination therapies for use in treating cancer |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN115089585A (zh) * | 2022-08-05 | 2022-09-23 | 中国科学院大学宁波华美医院 | Mdm2抑制剂rg7112联合依托泊苷在治疗肺癌中的应用 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| WO2024254156A1 (en) * | 2023-06-05 | 2024-12-12 | Kartos Therapeutics, Inc. | Treatment of endometrial cancer with mdm2 inhibitors |
| WO2025098488A1 (zh) * | 2023-11-09 | 2025-05-15 | 深圳艾欣达伟医药科技有限公司 | 上调p53蛋白表达或激活p53功能的药物与DNA烷化剂联用治疗癌症 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA12333A (en) | 2000-07-19 | 2004-04-06 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids. |
| EP1809282B1 (en) | 2004-10-18 | 2013-01-09 | Amgen, Inc | Thiadiazole compounds and methods of use |
| AU2007207743B2 (en) | 2006-01-18 | 2010-07-08 | Amgen Inc. | Thiazole compounds as protein kinase B (PKB) inhibitors |
| WO2008118454A2 (en) | 2007-03-23 | 2008-10-02 | Amgen Inc. | Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer |
| HUE028954T2 (en) | 2007-03-23 | 2017-01-30 | Amgen Inc | Heterocyclic compounds and their use |
| PT2139882E (pt) | 2007-03-23 | 2014-01-30 | Amgen Inc | Derivados de quinolina ou quinoxalina 3-substituídos e sua utilização como inibidores de fosfatidilinositol 3-cinase (pi3k) |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| CA2689092C (en) | 2007-06-07 | 2013-01-15 | Amgen Inc. | Raf kinase modulators and methods of use |
| CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
| CA2693473A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
| CA2694136C (en) | 2007-08-02 | 2013-09-17 | Amgen Inc. | Pi3 kinase modulators and methods of use |
| BRPI0821209A2 (pt) | 2007-12-19 | 2019-09-24 | Amgen Inc | composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor. |
| WO2009085230A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Inhibitors of pi3 kinase |
| WO2009126584A1 (en) | 2008-04-07 | 2009-10-15 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
| EP2307400B1 (en) | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitors of pi3 kinase |
| EP2387570A1 (en) | 2009-01-15 | 2011-11-23 | Amgen, Inc | Fluoroisoquinoline substituted thiazole compounds and methods of use |
| MX2011008674A (es) | 2009-02-18 | 2011-11-04 | Amgen Inc | Compuestos de indol/bencimidazol como inhibidores de quinasa mtor. |
| JP2012521354A (ja) | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| WO2010132598A1 (en) | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| JP2012531436A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用 |
| MX2011013901A (es) | 2009-06-25 | 2012-05-08 | Amgen Inc | Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k. |
| EP2445900B1 (en) | 2009-06-25 | 2016-03-02 | Amgen, Inc | Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases |
| JP2012531438A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | 複素環式化合物およびその使用 |
| NZ598758A (en) | 2009-09-11 | 2013-12-20 | Amgen Inc | N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| KR20120031734A (ko) * | 2010-09-27 | 2012-04-04 | 삼성전자주식회사 | 급성 골수성 백혈병 환자의 시타라빈 민감성을 예측하기 위한 키트 및 방법 |
| MX2013006020A (es) * | 2011-01-31 | 2013-10-01 | Celgene Corp | Composicion farmaceutica de analogos de citidina y metodos para su uso. |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| US9216170B2 (en) * | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| WO2013144923A1 (en) | 2012-03-30 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
| JP6417338B2 (ja) | 2013-02-19 | 2018-11-07 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物 |
| JP6266659B2 (ja) | 2013-02-28 | 2018-01-24 | アムジエン・インコーポレーテツド | 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 |
| WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| US20150031642A1 (en) | 2013-07-26 | 2015-01-29 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome i |
| SMT202200241T1 (it) * | 2013-11-11 | 2022-09-14 | Amgen Inc | Politerapia che include un inibitore di mdm2 e uno o più agenti farmaceuticamente attivi aggiuntivi per il trattamento di cancri |
-
2014
- 2014-11-11 SM SM20220241T patent/SMT202200241T1/it unknown
- 2014-11-11 SG SG10201902429PA patent/SG10201902429PA/en unknown
- 2014-11-11 KR KR1020217029928A patent/KR102473485B1/ko active Active
- 2014-11-11 US US15/035,438 patent/US20160287569A1/en not_active Abandoned
- 2014-11-11 NZ NZ758548A patent/NZ758548A/en not_active IP Right Cessation
- 2014-11-11 MX MX2020013670A patent/MX2020013670A/es unknown
- 2014-11-11 CN CN201480072891.XA patent/CN105934255A/zh active Pending
- 2014-11-11 DK DK14805743.3T patent/DK3068393T5/da active
- 2014-11-11 MA MA39094A patent/MA39094B1/fr unknown
- 2014-11-11 NZ NZ720766A patent/NZ720766A/en not_active IP Right Cessation
- 2014-11-11 HU HUE14805743A patent/HUE059351T2/hu unknown
- 2014-11-11 RS RS20220533A patent/RS63348B9/sr unknown
- 2014-11-11 HR HRP20220718TT patent/HRP20220718T1/hr unknown
- 2014-11-11 CA CA2930244A patent/CA2930244A1/en active Pending
- 2014-11-11 JP JP2016553270A patent/JP2016535795A/ja not_active Ceased
- 2014-11-11 WO PCT/US2014/065034 patent/WO2015070224A2/en not_active Ceased
- 2014-11-11 EA EA201690980A patent/EA036942B1/ru unknown
- 2014-11-11 ES ES14805743T patent/ES2916721T3/es active Active
- 2014-11-11 CN CN202011275297.4A patent/CN112933236A/zh active Pending
- 2014-11-11 EA EA202092456A patent/EA202092456A3/ru unknown
- 2014-11-11 SI SI201431961T patent/SI3068393T1/sl unknown
- 2014-11-11 EP EP14805743.3A patent/EP3068393B9/en active Active
- 2014-11-11 BR BR112016010564A patent/BR112016010564A2/pt not_active IP Right Cessation
- 2014-11-11 KR KR1020167015298A patent/KR102305351B1/ko not_active Expired - Fee Related
- 2014-11-11 PT PT148057433T patent/PT3068393T/pt unknown
- 2014-11-11 LT LTEPPCT/US2014/065034T patent/LT3068393T/lt unknown
- 2014-11-11 AU AU2014346354A patent/AU2014346354A1/en not_active Abandoned
- 2014-11-11 EP EP22154212.9A patent/EP4039256A1/en not_active Withdrawn
- 2014-11-11 PL PL14805743.3T patent/PL3068393T3/pl unknown
- 2014-11-11 TN TN2016000176A patent/TN2016000176A1/en unknown
- 2014-11-11 MX MX2016006025A patent/MX378969B/es unknown
- 2014-11-11 MY MYPI2016000850A patent/MY192088A/en unknown
- 2014-11-11 MX MX2020001550A patent/MX391859B/es unknown
- 2014-11-11 MX MX2019009853A patent/MX393610B/es unknown
- 2014-11-11 KR KR1020227041845A patent/KR20220167335A/ko not_active Ceased
- 2014-11-11 UA UAA201606309A patent/UA120750C2/uk unknown
- 2014-11-11 AP AP2016009243A patent/AP2016009243A0/en unknown
-
2016
- 2016-05-06 MX MX2022012320A patent/MX2022012320A/es unknown
- 2016-05-06 MX MX2022008175A patent/MX2022008175A/es unknown
- 2016-05-10 IL IL245568A patent/IL245568B/en unknown
- 2016-05-11 CL CL2016001131A patent/CL2016001131A1/es unknown
- 2016-05-11 PH PH12016500871A patent/PH12016500871A1/en unknown
- 2016-05-17 ZA ZA2016/03342A patent/ZA201603342B/en unknown
-
2018
- 2018-12-21 US US16/229,150 patent/US10881648B2/en not_active Expired - Fee Related
-
2019
- 2019-04-17 JP JP2019078325A patent/JP2019142916A/ja active Pending
-
2020
- 2020-02-24 AU AU2020201321A patent/AU2020201321B2/en not_active Ceased
- 2020-10-13 JP JP2020172367A patent/JP6972274B2/ja not_active Expired - Fee Related
-
2021
- 2021-08-16 IL IL285646A patent/IL285646A/en unknown
- 2021-09-09 US US17/470,136 patent/US20220280495A1/en not_active Abandoned
- 2021-11-01 JP JP2021178554A patent/JP2022009805A/ja active Pending
-
2022
- 2022-03-03 AU AU2022201495A patent/AU2022201495A1/en not_active Abandoned
- 2022-06-08 CY CY20221100397T patent/CY1125358T1/el unknown
-
2023
- 2023-01-13 JP JP2023003579A patent/JP2023033414A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535795A5 (enExample) | ||
| HRP20220718T1 (hr) | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka | |
| CL2019000056A1 (es) | Sales y formas cristalinas del ácido 2-(3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-(s)-1(isopropilsufonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético; proceso de preparación de una de las sales; composición farmacéutica que comprende; útiles para tratar cáncer. (solicitud divisional 201503589) | |
| ME02150B (me) | Derivati piperidinona kao inhibitori mdm2 za lečenje kancera | |
| RU2014120792A (ru) | Способ лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2014114295A5 (enExample) | ||
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| TW201612158A (en) | Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof | |
| JP2016539157A5 (enExample) | ||
| JP2016525102A5 (enExample) | ||
| NZ630589A (en) | Methods of treating alzheimer’s disease and pharmaceutical compositions thereof | |
| JP2017504611A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2013542261A5 (enExample) | ||
| PE20170312A1 (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso | |
| JP2016508134A5 (enExample) | ||
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| RU2016141569A (ru) | Комбинации | |
| CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
| WO2016109217A3 (en) | Btk inhibitors | |
| EA201100358A1 (ru) | Дабигатран для чрескожной хирургической катетеризации сердца | |
| JP2016523260A5 (enExample) | ||
| MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
| MX2014014969A (es) | Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral. | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 |